Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
28.84
-0.26 (-0.89%)
At close: Oct 16, 2026, 4:00 PM EDT
28.37
-0.47 (-1.64%)
After-hours: Oct 16, 2026, 7:58 PM EDT
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $129.86M in the quarter ending June 30, 2026, with 59.33% growth. This brings the company's revenue in the last twelve months to $463.98M, up 76.11% year-over-year. In the year 2025, Arcutis Biotherapeutics had annual revenue of $376.07M with 91.34% growth. That makes Arcutis Biotherapeutics the 11,628th largest company in the world by revenue and 2,337th in the United States.
Revenue (ttm)
$463.98M
Revenue Growth
+76.11%
P/S Ratio
7.81
Revenue / Employee
$1,310,681
Employees
354
Market Cap
3.62B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.07M | 179.53M | 91.34% |
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Acadia Pharmaceuticals | 1.14B |
| Telix Pharmaceuticals | 890.79M |
| Tarsus Pharmaceuticals | 606.33M |
| IDEAYA Biosciences | 234.13M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
ARQT News
- 2 days ago - Arcutis Biotherapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 2 days ago - Arcutis Biotherapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 8 days ago - Arcutis Biotherapeutics presents data across Zoryve portfolio - TheFly
- 8 days ago - Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical - GlobeNewsWire
- 11 days ago - Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award - GlobeNewsWire
- 14 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Arcutis Biotherapeutics partners with Simone Biles for new awareness campaign - TheFly
- 4 weeks ago - Arcutis Biotherapeutics falls -5.1% - TheFly